|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Papers In Press, published online ahead of print July 11, 2008 J. Lipid Res., doi:10.1194/jlr.M800075-JLR200
Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1679
Corresponding Author: bvanlent{at}mednet.ucla.edu
4F is an anti-inflammatory, apoA-I mimetic peptide that is active in vivo at nanomolar concentrations in the presence of a large molar excess of apoA-I. Physiologic concentrations (~ 35 µM) of human apoA-1 did not inhibit the production of LDL-induced monocyte chemotactic activity by human aortic endothelial cell cultures, but adding nanomolar concentrations of 4F in the presence of ~ 35 µM apoA-1 significantly reduced this inflammatory response. We analyzed lipid binding by surface plasmon resonance. The anti-inflammatory 4F peptide bound oxidized lipids with much higher affinity than did apoA-I. Initially, we examined the binding of PAPC (1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphatidylcholine) and observed that its oxidized products bound 4F with an affinity that was ~ 4-6 orders of magnitude higher than that of apoA-I. This high binding affinity was confirmed in studies with defined lipids and phospholipids. 3F-2 and 3F14 are also amphipathic alpha-helical octadecapeptides, but 3F-2 inhibits atherosclerosis in mice and 3F14 does not. Like 4F, 3F-2 also bound oxidized phospholipids with very high affinity, whereas 3F14 resembled apoA-I. The extraordinary ability of 4F to bind pro-inflammatory oxidized lipids likely accounts for its remarkable anti-inflammatory properties.
This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||